Northern Trust Corp Lumos Pharma, Inc. Transaction History

Northern Trust Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$6.84 - $10.04 $6,894 - $10,120	-1,008 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$7.36 - $11.36 $5,505 - $8,497	-748 Reduced 42.6%	1,008 $10,000
Q2 2021 Aug 13, 2021	SELL	$9.75 - $13.44 $11,739 - $16,181	-1,204 Reduced 40.68%	1,756 $17,000
Q1 2021 May 12, 2021	SELL	$11.58 - $31.11 $105,621 - $283,754	-9,121 Reduced 75.5%	2,960 $35,000
Q4 2020 Feb 11, 2021	BUY	$13.61 - $35.91 $122,476 - $323,154	8,999 Added 291.99%	12,081 $432,000
Q3 2020 Nov 16, 2020	SELL	$13.25 - $16.5 $119 - $148	-9 Reduced 0.29%	3,082 $43,000
Q2 2020 Aug 14, 2020	SELL	$7.76 - $16.99 $1,482 - $3,245	-191 Reduced 5.82%	3,091 $51,000
Q1 2020 May 14, 2020	BUY	$0.89 - $8.85 $2,920 - $29,045	3,282 New	3,282 $28,000

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.